BioNTech wants “to help eradicate malaria” by using the same breakthrough mRNA technology it used to develop its coronavirus vaccine, the pharmaceutical company said on Monday. The Germany-based group said it aimed to begin clinical malaria vaccine trials by the end of 2022. If successful, the shot could be a major development in the fight against malaria, which kills more than 400,000 people a year — mainly young children in Africa. The disease is caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. “We will do whatever it takes to develop a safe and effective mRNA-based malaria vaccine that will prevent the disease, reduce mortality and ensure a sustainable solution for the African continent and other regions affected by this disease,” BioNTech CEO Ugur Sahin said in a statement. Scientists believe mRNA technology, which prompts an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against several diseases. Using this technology is also a faster way of developing a vaccine than traditional methods and could bring an end to the decades-long search for a reliable malaria shot.
SOURCE: DEUTSCHE WELLE
More Stories
The Marshall Nature Reserve Gives a Different Glimpse of the Sudanese Capital
The Journey of Moving Tanzanians Around
Correcting Kinshasa’s Commodity Crisis
Can African Leaders Rate Themselves?
First Black African to Win Grand Tour Stage
Financing Dangote’s Fertiliser Dream Tougher than Expected
This is a Moment for the Women of Kenya
US Support in Somalia Couldn’t Have Come at a Better Time
A Symbol of Sudan’s Resistance
Families of Trapped Miners in Limbo
Google Translate Announces an Addition of 10 Languages Spoken in Africa
All Four Tourists Reported Missing in the Fish River Canyon have been Accounted For